Holen Sie sich die Stockscreener-App
2.74
2.84%
-0.08
Handel nachbörslich:
2.68
-0.06
-2.19%
Schlusskurs vom Vortag:
$2.82
Offen:
$2.82
24-Stunden-Volumen:
414.58K
Relative Volume:
1.18
Marktkapitalisierung:
$151.63M
Einnahmen:
$163.78M
Nettoeinkommen (Verlust:
$25.88M
KGV:
4.2154
EPS:
0.65
Netto-Cashflow:
$-28.66M
1W Leistung:
-6.16%
1M Leistung:
-23.57%
6M Leistung:
-60.06%
1J Leistung:
-66.34%
1-Tages-Spanne:
$2.645
$2.86
1-Wochen-Bereich:
$2.645
$2.99
52-Wochen-Spanne:
$2.645
$9.55
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Firmenname
Voyager Therapeutics Inc
Sektor
Branche
Telefon
857-259-5340
Adresse
75 HAYDEN AVENUE, LEXINGTON, MA
Vergleichen Sie VYGR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
2.74 | 161.58M | 163.78M | 25.88M | -28.66M | 0.65 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-02 | Eingeleitet | Citigroup | Buy |
| 2024-11-29 | Fortgesetzt | Wedbush | Outperform |
| 2024-10-16 | Eingeleitet | Leerink Partners | Outperform |
| 2024-03-26 | Eingeleitet | Guggenheim | Buy |
| 2024-03-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-07 | Eingeleitet | Citigroup | Buy |
| 2024-01-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-05-10 | Eingeleitet | Truist | Buy |
| 2023-03-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-10-07 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-02-03 | Herabstufung | BTIG Research | Buy → Neutral |
| 2021-02-03 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-24 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2020-12-23 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-11-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-11-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-03-19 | Eingeleitet | The Benchmark Company | Buy |
| 2020-02-06 | Eingeleitet | Oppenheimer | Outperform |
| 2018-11-15 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-09-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-06-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-03-12 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-02-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-11-28 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-10-31 | Eingeleitet | Robert W. Baird | Outperform |
| 2017-10-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-10-23 | Bestätigt | Stifel | Buy |
| 2017-10-12 | Eingeleitet | Raymond James | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-28 | Fortgesetzt | Stifel | Buy |
Alle ansehen
Voyager Therapeutics Inc Aktie (VYGR) Neueste Nachrichten
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Sold by Jane Street Group LLC - Defense World
Voyager Therapeutics stock plunges to 52-week low of $2.71 By Investing.com - Investing.com Canada
Voyager Therapeutics stock plunges to 52-week low of $2.71 - Investing.com
It's Unlikely That The CEO Of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Will See A Huge Pay Rise This Year - simplywall.st
Northern Trust Corp Raises Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
With 46% ownership, Voyager Therapeutics, Inc. (NASDAQ:VYGR) has piqued the interest of institutional investors - Yahoo Finance
Cubist Systematic Strategies LLC Buys New Shares in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Tower Research Capital LLC TRC Increases Stock Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of “Buy” from Brokerages - Defense World
Voyager Therapeutics (VYGR) Showcases Breakthrough in Gene Thera - GuruFocus
Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain - GlobeNewswire
Revolutionary Brain Drug Delivery: Voyager's New Gene Therapy Shows 400x Improvement in Landmark Research - Stock Titan
Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (ANIP), Voyager Therapeutics (VYGR) and Privia Health Group (PRVA) - The Globe and Mail
Q2 EPS Forecast for Voyager Therapeutics Reduced by Analyst - Defense World
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock Position Increased by Dimensional Fund Advisors LP - Defense World
FY2025 EPS Estimates for VYGR Increased by Cantor Fitzgerald - Defense World
Leerink Partnrs Has Negative Outlook of VYGR Q2 Earnings - Defense World
Q2 EPS Estimates for Voyager Therapeutics Lifted by Wedbush - Defense World
Voyager Therapeutics Reports Q1 2025 Financial Results - TipRanks
Barclays PLC Buys 10,328 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Analysts Have Conflicting Sentiments on These Healthcare Companies: Omnicell (OMCL), Voyager Therapeutics (VYGR) and Masimo (MASI) - The Globe and Mail
Voyager Therapeutics Inc earnings missed by $0.08, revenue fell short of estimates - Investing.com India
Raymond James Financial Inc. Takes $746,000 Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics: Q1 Earnings Snapshot - Connecticut Post
Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Voyager Reports First Quarter 2025 Financial and Operating Results - The Manila Times
Voyager Therapeutics Q1 2025 Financial and Operating Results - TradingView
Voyager Therapeutics, Inc. SEC 10-Q Report - TradingView
Legal & General Group Plc Has $109,000 Stock Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer - Stock Titan
BlackRock, Inc. Reduces Stake in Voyager Therapeutics Inc - GuruFocus
Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annua - GuruFocus
Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting | VYGR Stock News - GuruFocus
Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting - GlobeNewswire
Voyager Therapeutics Presents New Data on Tau Silencing Gene Therapy VY1706 and Anti-Amyloid Gene Therapy at ASGCT Annual Meeting - Nasdaq
Revolutionary Alzheimer's Gene Therapy Achieves 73% Tau Reduction: Voyager's Breakthrough Data Revealed - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
JPMorgan Chase & Co. Decreases Stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Geode Capital Management LLC Grows Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics Inc (VYGR) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... - Yahoo Finance
Voyager Therapeutics Inc (VYGR) Q4 2024 Earnings Call Highlights: Strong Financial Position and Promising Pipeline Developments - GuruFocus
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Franklin Resources Inc. Reduces Stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
FY2026 Earnings Estimate for VYGR Issued By Leerink Partnrs - Defense World
Vanguard Group Inc. Grows Stock Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Wellington Management Group LLP Boosts Stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
American Century Companies Inc. Has $696,000 Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics stock hits 52-week low at $2.81 - Investing.com
Voyager Therapeutics stock hits 52-week low at $2.81 By Investing.com - Investing.com Canada
Finanzdaten der Voyager Therapeutics Inc-Aktie (VYGR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):